Frequently Asked Questions on Microarray Patches (MAPs)
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.
TAG Comments at UN High-Level Meeting on Antimicrobial Resistance Hearing
TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.
TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
Community Engagement on Microarray Patches
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.
Going Behind the Scenes at TAG
Follow along with one of our staff members on a typical day, and you'll see the difference you make as a TAG donor and partner.
Research in Action Awards Honorees
1997 Michael Palm* Dr. David Ho 1998 Wafaa El-Sadr Dr. Mathilde Krim* 1999 Dr. Harold Varmus Irene Diamond* Spencer Cox* 2000 Tom Viola, BC/EFA Dr. Anthony S. Fauci Lynda M. Dee, Esq. 2001 Gregg Gonsalves Michael Cunningham Dr. Art Ammann*…
Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.
Getting Better Faster: Delivering on the Promise of New TB Treatments – A Report from the 1/4/6×24 Campaign
This report marks the midway point of the 1/4/6x24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.
Story: HIV “completely eliminated” from cells in a laboratory dish with CRISPR technology
March 2024 Media coverage: Scientists say they can cut HIV out of cells - Michelle Roberts, BBC, March 20, 2024 HIV cure breakthrough as virus eliminated from cells in laboratory - Nina Massey, The Independent, March 20, 2024 Hopes of…
